ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Agnandji ST et al. 2016. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 374: 1647–1660.
-
2.
ElSherif MS et al. 2017. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ 189: E819–E827.
-
3.
Regules JA et al. 2017. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med 376: 330–341.
-
4.
Huttner A et al. 2015. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 15: 1156–1166.
-
5.
Kennedy SB et al. 2017. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med 377: 1438–1447.
-
6.
Samai M et al. 2018. The Sierra Leone trial to introduce a vaccine against Ebola: an evaluation of rVSVΔG-ZEBOV-GP vaccine tolerability and safety during the west Africa Ebola outbreak. J Infect Dis 217 (Suppl 1): S6–S15.
-
7.
Henao-Restrepo AM et al. 2017. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 389: 505–518.
-
8.
European Medicines Agency (EMA), 2019. Summary of Opinion (Initial Authorisation): Ervebo Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP, Live). Available at: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ervebo_en.pdf. Accessed June 12, 2020.
-
9.
World Health Organization, 2019. WHO prequalifies Ebola vaccine, paving the way for its use in high-risk countries. Geneva, Switzerland: WHO. Available at: https://www.who.int/news-room/detail/12-11-2019-who-prequalifies-ebola-vaccine-paving-the-way-for-its-use-in-high-risk-countries. Accessed June 12, 2020.
-
10.
Merck & Co., Inc., Kenilworth, NJ, 2019. Merck Announces FDA Approval for ERVEBO® (Ebola Zaire Vaccine, Live). Available at: https://www.mrknewsroom.com/news-release/ebola/merck-announces-fda-approval-ervebo-ebola-zaire-vaccine-live. Accessed June 12, 2020.
-
11.
Merck & Co., Inc., Kenilworth. NJ, 2020. ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification. Available at: https://www.mrknewsroom.com/news-release/ebola/ervebo-ebola-zaire-vaccine-live-now-registered-four-african-countries-within-90-d. Accessed June 12, 2020.
-
12.
Centers for Disease Control and Prevention, Division of Select Agents and Toxins, Animal and Plant Health Inspection Service, Agricultural Select Agent Program, 2017. Guidance on the Inactivation or Removal of Select Agents and Toxins for Future Use. Available at: https://www.selectagents.gov/resources/Inactivation_Guidance.pdf. Accessed June 12, 2020.
-
13.
Grant-Klein RJ, Antonello J, Nichols R, Dubey S, Simon J, 2019. Effect of gamma irradiation on the antibody response measured in human serum from subjects vaccinated with recombinant vesicular stomatitis virus-zaire Ebola virus envelope glycoprotein vaccine. Am J Trop Med Hyg 101: 207–213.
-
14.
Halperin SA et al. 2017. Six-month safety data of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J Infect Dis 215: 1789–1798.
-
15.
Halperin SA et al. 2019. Immunogenicity, lot consistency, and extended safety of rVSVΔG-ZEBOV-GP vaccine: a phase 3 randomized, double-blind, placebo-controlled study in healthy adults. J Infect Dis 220: 1127–1135.
-
16.
Heppner DG Jr et al. 2017. Safety and immunogenicity of the rVSVΔG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis 17: 854–866.
-
17.
Li L, 1989. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45: 255–268.
-
18.
Lin L, Torbeck LD, 1998. Coefficient of accuracy and concordance correlation coefficient: new statistics for methods comparison. PDA J Pharm Sci Technol 52: 55–59.
-
19.
Tan C, Iglewicz B, 1999. Measurement-methods comparisons and linear statistical relationship. Technometrics 41: 192–201.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 528 | 47 | 7 |
| Full Text Views | 284 | 184 | 8 |
| PDF Downloads | 203 | 125 | 11 |
Effects of Gamma Irradiation of Human Serum Samples from rVSVΔG-ZEBOV-GP (V920) Ebola Virus Vaccine Recipients on Plaque-Reduction Neutralization Assays
ABSTRACT
Gamma irradiation (GI) is included in the CDC guidance on inactivation procedures to render a group of select agents and toxins nonviable. The Ebola virus falls within this group because it potentially poses a severe threat to public health and safety. To evaluate the impact of GI at a target dose of 50 kGy on neutralizing antibody titers induced by the rVSVΔG-ZEBOV-GP vaccine (V920), we constructed a panel of 48 paired human serum samples (GI-treated versus non–GI-treated) from healthy participants selected from a phase 3 study of V920 (study V920-012; NCT02503202). Neutralizing antibody titers were determined using a validated plaque-reduction neutralization test. GI of sera from V920 recipients was associated with approximately 20% reduction in postvaccination neutralizing antibody titers. GI was not associated with any change in pre-vaccination neutralizing antibody titers.
- Supplemental Materials (DOCX 225.37 KB)
Author Notes
Disclosure: R. J. G.-K., J. A., S. D., and J. K. S. are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, and may own stock/stock options in Merck & Co., Inc., Kenilworth, NJ. R. N. has received personal fees from New Link Genetics as a consultant.
Financial support: This study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ. This project has been funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; and Biomedical Advanced Research and Development Authority, under contract no. HHSO100201500002C. Medical writing assistance, under the direction of the authors, was provided by Adele Blair, of CMC AFFINITY, McCann Health Medical Communications, in accordance with Good Publication Practice (GPP3) guidelines. This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ.
Authors’ addresses: Rebecca J. Grant-Klein, Joseph Antonello, Sheri Dubey, and Jakub K. Simon, Merck & Co., Inc., Kenilworth, NJ, E-mails: rebecca.klein1@merck.com, joseph_antonello@merck.com, sheri_dubey@merck.com, and jakub.simon@merck.com. Rick Nichols, Crozet BioPharma, Devens, MA, E-mail: rick.nichols@crozetbiopharma.com.